We discovered that the high expression of ADCY1 can significantly increase cisplatin sensitivity in cisplatin-resistant lung cancer, which is in accordance with the results revealed by the down-regulation of ADCY1 in lung cancer cells. This evidence concerns the gene ADCY1 and lung cancer.